Literature DB >> 25088890

Pure red cell aplasia induced by lamivudine without the influence of zidovudine in a patient infected with human immunodeficiency virus.

Kiwamu Nakamura1, Masao Tateyama, Daisuke Tasato, Shusaku Haranaga, Maki Tamayose, Satomi Yara, Futoshi Higa, Jiro Fujita.   

Abstract

We herein report the case of a patient with human immunodeficiency virus infection and acquired immune deficiency syndrome who was diagnosed with drug-induced pure red cell aplasia consequent to lamivudine treatment. The patient was admitted to our hospital for treatment of increasing shortness of breath following physical effort. Upon admission, routine blood tests revealed a hemoglobin level of 7.6 g/dL and a hematocrit proportion of 21.2%, with normal leukocyte and platelet counts. After stopping the lamivudine treatment, the patient's hemoglobin concentration and hematocrit level returned to normal. A bone marrow examination showed an exclusive reduction in erythrocyte formation. This case indicates that lamivudine can induce severe anemia without the influence of zidovudine.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25088890     DOI: 10.2169/internalmedicine.53.2460

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  3 in total

1.  Assessment of non-standard HIV antiretroviral therapy regimens at Lighthouse Trust in Lilongwe, Malawi.

Authors:  B S Barnett; T Chaweza; H Tweya; W Ngambi; S Phiri; M C Hosseinipour
Journal:  Malawi Med J       Date:  2016-03       Impact factor: 0.875

2.  Refractory anemia in human immunodeficiency virus: Expect the unexpected.

Authors:  Sumeet Prakash Mirgh; Vikas A Mishra; Virti D Shah; Jehangir Soli Sorabjee
Journal:  J Family Med Prim Care       Date:  2016 Jul-Sep

3.  A case series of emtricitabine-induced pure red cell aplasia.

Authors:  Nithendra Manickchund; Camille du Plessis; Melanie-Anne A John; Thandekile C Manzini; Bernadett I Gosnell; Mahomed-Yunus S Moosa
Journal:  South Afr J HIV Med       Date:  2021-08-30       Impact factor: 2.744

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.